KR102197478B1 - 식도암을 검출 및 치료하기 위한 조성물 및 방법 - Google Patents

식도암을 검출 및 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102197478B1
KR102197478B1 KR1020187020013A KR20187020013A KR102197478B1 KR 102197478 B1 KR102197478 B1 KR 102197478B1 KR 1020187020013 A KR1020187020013 A KR 1020187020013A KR 20187020013 A KR20187020013 A KR 20187020013A KR 102197478 B1 KR102197478 B1 KR 102197478B1
Authority
KR
South Korea
Prior art keywords
cdr
antibody
progastrin
preferentially
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187020013A
Other languages
English (en)
Korean (ko)
Other versions
KR20180108586A (ko
Inventor
알렉산더 프뢰르
Original Assignee
프로가스트린 에 캔서스 에스.에이 알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로가스트린 에 캔서스 에스.에이 알.엘. filed Critical 프로가스트린 에 캔서스 에스.에이 알.엘.
Priority to KR1020207037405A priority Critical patent/KR102430893B1/ko
Publication of KR20180108586A publication Critical patent/KR20180108586A/ko
Application granted granted Critical
Publication of KR102197478B1 publication Critical patent/KR102197478B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57557—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187020013A 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법 Active KR102197478B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207037405A KR102430893B1 (ko) 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15307189.9 2015-12-31
EP15307189 2015-12-31
EP16305139.4 2016-02-05
EP16305139 2016-02-05
PCT/EP2017/050037 WO2017114976A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207037405A Division KR102430893B1 (ko) 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20180108586A KR20180108586A (ko) 2018-10-04
KR102197478B1 true KR102197478B1 (ko) 2021-01-04

Family

ID=57821946

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187020013A Active KR102197478B1 (ko) 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법
KR1020207037405A Active KR102430893B1 (ko) 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207037405A Active KR102430893B1 (ko) 2015-12-31 2017-01-02 식도암을 검출 및 치료하기 위한 조성물 및 방법

Country Status (14)

Country Link
US (2) US11789021B2 (enExample)
EP (2) EP3848709B1 (enExample)
JP (2) JP7018885B2 (enExample)
KR (2) KR102197478B1 (enExample)
CN (1) CN108700589A (enExample)
AU (2) AU2017204686B2 (enExample)
BR (1) BR112018013272A2 (enExample)
CA (2) CA3193481A1 (enExample)
EA (1) EA037032B1 (enExample)
ES (2) ES3003287T3 (enExample)
PL (1) PL3397967T3 (enExample)
SG (1) SG11201805263TA (enExample)
WO (1) WO2017114976A1 (enExample)
ZA (1) ZA201804142B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018264A1 (en) * 2015-12-31 2024-01-18 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
EP3720879B1 (en) * 2017-12-05 2022-05-11 Progastrine et Cancers S.à r.l. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2018381046B2 (en) 2017-12-08 2025-10-02 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
WO2019166499A1 (en) 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
CA3093053A1 (en) * 2018-03-13 2019-09-19 Creatv Microtech, Inc. Methods for monitoring treatment response and disease progression in subjects using circulating cells
KR102167078B1 (ko) * 2019-07-19 2020-10-16 (주)파즈코리아 혈액 샘플 이송 장치
US20220356532A1 (en) * 2019-10-24 2022-11-10 The Johns Hopkins University Compositions and methods for detecting and treating esophageal cancer
JP7287532B2 (ja) * 2020-08-04 2023-06-06 王子ホールディングス株式会社 トイレットロール

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110085986A1 (en) 2009-10-13 2011-04-14 Pomila Singh Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides
WO2011083091A2 (en) 2010-01-08 2011-07-14 Bioréalités S.A.S. Methods for treating pancreatic cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1525868A (zh) * 2001-07-09 2004-09-01 埃弗顿有限公司 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
EP2010569A4 (en) * 2006-03-20 2009-09-09 Xoma Technology Ltd HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
SG184092A1 (en) * 2010-03-24 2012-10-30 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
ES2871092T3 (es) 2010-07-26 2021-10-28 Progastrine Et Cancers S A R L Métodos y composiciones para la terapia del cáncer de hígado
FI20145550A7 (fi) 2014-06-13 2015-12-14 Biohit Oyj Gastriini-17 käyttö biomarkkerina atrofiselle gastriitille ja usealle sen seurauksena kohonneelle riskille
WO2016066671A1 (en) * 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110085986A1 (en) 2009-10-13 2011-04-14 Pomila Singh Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides
WO2011083091A2 (en) 2010-01-08 2011-07-14 Bioréalités S.A.S. Methods for treating pancreatic cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
esophageal cancer, progastrin, anti-progastrin antibody, anti-hPG

Also Published As

Publication number Publication date
EA201891527A1 (ru) 2019-01-31
ES2861587T3 (es) 2021-10-06
EP3848709A1 (en) 2021-07-14
KR102430893B1 (ko) 2022-08-09
EP3397967B1 (en) 2020-12-30
CA3193481A1 (en) 2017-07-06
JP2022064969A (ja) 2022-04-26
AU2017204686A1 (en) 2018-07-05
AU2020202296B2 (en) 2022-06-02
CN108700589A (zh) 2018-10-23
PL3397967T3 (pl) 2021-06-28
US20240085423A1 (en) 2024-03-14
CA3009785A1 (en) 2017-07-06
EP3848709B1 (en) 2024-12-04
US11789021B2 (en) 2023-10-17
EP3848709C0 (en) 2024-12-04
JP7363007B2 (ja) 2023-10-18
KR20180108586A (ko) 2018-10-04
SG11201805263TA (en) 2018-07-30
AU2020202296A1 (en) 2020-04-23
JP2019505785A (ja) 2019-02-28
EA037032B1 (ru) 2021-01-28
JP7018885B2 (ja) 2022-02-14
BR112018013272A2 (en) 2018-12-11
US20190011447A1 (en) 2019-01-10
AU2017204686B2 (en) 2020-04-30
EP3397967A1 (en) 2018-11-07
WO2017114976A1 (en) 2017-07-06
ZA201804142B (en) 2019-11-27
ES3003287T3 (en) 2025-03-10
KR20210002363A (ko) 2021-01-07

Similar Documents

Publication Publication Date Title
US20240085423A1 (en) Compositions and methods for detecting and treating esophageal cancer
AU2021250840B2 (en) Compositions and methods for detecting and treating ovarian cancer
US20240402181A1 (en) Compositions and methods for detecting and treating gastric cancer
US20240018264A1 (en) Compositions and methods for detecting and treating ovarian cancer
HK1262046B (en) Compositions and methods for detecting and treating esophageal cancer
HK1262046A1 (en) Compositions and methods for detecting and treating esophageal cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000